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1422 The Journal of Thoracic and CardObjective: Resistance to histone deacetylase inhibitors in non–small cell lung cancer
is mediated in part through activation of nuclear factor-B through a phosphatidyl-
inositol 3-kinase/Akt–dependent pathway. We hypothesize that inhibition of phos-
phatidylinositol 3-kinase/Akt will sensitize non–small cell lung cancer cells to
histone deacetylase inhibitor-induced apoptosis.
Methods: Tumorigenic non–small cell lung cancer cell lines H157, H358, H460, and
A549 were treated with nothing, the histone deacetylase inhibitor butyrate, the
phosphatidylinositol 3-kinase/Akt inhibitor LY294002, or both compounds. Nuclear
factor-B activity was assessed by reporter gene assays and reverse transcriptase-
polymerase chain reaction of the nuclear factor-B dependent genes cIAP-2, Bfl/A1,
and MnSOD. Whole cell extracts were immunoblotted for phospho-Akt, Akt, and
phospho-ser/thr-Akt substrate. Cell death and apoptosis were measured by crystal
violet staining, caspase-3 activity, and DNA fragmentation. A549 non–small cell
lung cancer xenografts were created in athymic nude mice, and tumor growth was
assessed after treatments as noted above. Explanted tumors underwent terminal
deoxynucleotide transferase-mediated dUTP nick-end labeling and Western blot
analyses for apoptosis assessment and drug target validation, respectively.
Results: Butyrate activated nuclear factor-B–dependent transcription, and
LY294002 abrogated this effect. Combined treatment induced more apoptosis and
cell death in vitro compared with either drug alone as measured by caspase-3, DNA
fragmentation, and clonogenic survival. Combined butyrate and LY294002 was
tumoristatic in vivo, but all other xenografts grew. This decreased tumor growth
correlated with more apoptosis in the xenografts treated with combined therapy.
Tumor levels of phospho-Akt and acetylated histone H3 were decreased and
increased, respectively, in xenografts treated with combined therapy.
Conclusions: Combined histone deacetylase inhibitor and phosphatidylinositol 3-
kinase/Akt pathway inhibition sensitized non–small cell lung cancer xenografts to
apoptosis. Further investigations of this combined therapy are warranted as new
pharmacologic phosphatidylinositol 3-kinase/Akt pathway inhibitors are developed.
We and others previously showed that the inflammatory and anti-apoptotictranscription factor, nuclear factor (NF)-B, plays a significant role in theresistance of non–small cell lung cancer (NSCLC) to chemotherapy.1-3
Direct molecular inhibition of NF-B using an adenovirally delivered inhibitor of
NF-B dramatically sensitizes NSCLC cells to apoptosis induced by traditional
chemotherapy agents such as gemcitabine, as well as novel biologic agents includ-
ing the histone deacetylase inhibitors (HDIs) butyrate and suberoylanilide hydro-
xamic acid.1,4 Although adenoviral delivery of an inhibitor of NF-B may be
efficacious in preclinical studies, clinical application is conceptually difficult and
problematic for a number of reasons.
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TSActivation of NF-B occurs through a number of dispar-
ate cell signaling pathways that include ligands binding
surface receptors and stress responses emanated from the
nucleus in response to DNA damage.5 It has been shown
that the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
activates NF-B at both the cytoplasmic and nuclear lev-
els.4,6,7 The PI3K family of membrane-bound protein ki-
nases are stimulated directly or indirectly by cell surface
receptor tyrosine kinases that respond to extracellular
growth signals.8 The biologic consequences of Akt activa-
tion collectively support cell survival through inhibition of
the pro-apoptotic proteins BAD, caspase-9, and forkhead, in
addition to activating the anti-apoptotic transcription factor
NF-B.9-11 Recently, we demonstrated that PI3K/Akt has
an important role in activating NF-B after treatment with
HDIs.4
HDIs have been shown to induce growth arrest, differ-
entiation, and apoptosis in malignant cells and are now the
focus of phase I and II trials either alone or in combination
with other compounds. We and others previously demon-
strated that treatment of NSCLC with HDIs as single-agent
therapy is ineffective in vitro and in vivo.12-14 This relates,
in part, to the activation of NF-B by the HDIs, which
attenuates proapoptotic signals induced by these com-
pounds. Realizing that HDIs activate NF-B through signal
transduction pathways involving PI3K/Akt, we hypothe-
sized that the pharmacologic inhibition of PI3K/Akt using
LY294002 (LY) would sensitize NSCLC to HDI-induced
apoptosis in our in vitro and in vivo NSCLC model
systems.
Materials and Methods
Cell Culture Reagents and Plasmids
Four cell lines representing different NSCLC histologic subtypes
(NCI-H157 [squamous cell], NCI-H358 [bronchioloalveolar cell],
NCI-H460 [large cell], and NCI-A549 [unknown histology]), ob-
tained from the American Type Culture Collection, were cultured
in Roswell Park Memorial Institute 1640 (Invitrogen, Carlsbad,
Calif) supplemented with 10% fetal bovine serum (HyClone Lab-
Abbreviations and Acronyms
GSK  phospho-ser/thr-Akt substrate
HDI  histone deacetylase inhibitor
LY  LY294002
NF-B  nuclear factor-B
NSCLC  non–small cell lung cancer
PI3K  phosphatidylinositol 3-kinase
RT-PCR  reverse transcriptase-polymerase chain
reaction
TUNEL  terminal deoxynucleotide transferase-
mediated dUTP nick-end labelingoratories, Logan, UT) and penicillin/streptomycin. The full-length
The Journal of ThoracicGal4/p65-luciferase construct contains 4 Gal-4 DNA consensus
binding sites derived from the yeast GAL-4 gene promoter cloned
upstream of luciferase cDNA. The Gal4-p65 fusion protein con-
sists of a yeast Gal-4 DNA-binding domain fused to full-length
p65 (1-551) and was described previously.12 Antibodies against
MnSOD and acetyl-H3 were obtained from Upstate Biotechnology
(Lake Placid, NY). Antibodies against Akt, phospho-Akt, and
phospho-ser/thr-Akt substrate (GSK) were obtained from Cell
Signaling (Beverly, Mass). The antibody against RNA Pol II
(C-21) was obtained from Santa Cruz Biotechnology (Santa Cruz,
Calif). Sodium butyrate and anti--tubulin antibodies were pur-
chased from Sigma (St Louis, Mo), and LY was purchased from
Calbiochem (La Jolla, Calif).
Luciferase Reporter Gene Assays
NSCLC cells at 60% to 80% confluency were transiently trans-
fected with 0.3 g DNA per well using Polyfect (Qiagen, Valen-
cia, Calif) according to the manufacturer’s instructions. Six hours
after the start of transfection, additional media containing the
appropriate pharmacologic agents were added. Twenty-four hours
after transfection, cells were washed once with 1 phosphate-
buffered saline and lysed in luciferase reporter buffer (Promega,
Madison, Wis). Cells were then snap-frozen at 80°C and subse-
quently thawed in a 37°C water bath. Extracts were collected and
cleared by centrifugation at 13,200 rpm. Protein concentrations
were determined with a Pierce BCA protein assay kit reagent
(Pierce, Rockford, Ill). Luciferase assays were performed by using
the substrate D-Luciferin (Promega), and relative light units were
measured with an Orion Microplate Luminometer, (Berthold De-
tection Systems, Pforzheim Germany). Luminescence was normal-
ized to protein concentration, and values were reported as the mean
standard error of mean of triplicate experiments.
Reverse Transcriptase–Polymerase Chain Reaction
NCSLC cells were treated for 12 hours with nothing, butyrate (500
mol/L), LY (25 mol/L), or both compounds. Cells were lysed
with Trizol (Invitrogen), and proteins were extracted with chloro-
form. RNAs were precipitated with isopropanol and washed with
70% ethanol. cDNAs were created using the Advantage reverse
transcriptase–polymerase chain reaction (RT-PCR) enzyme (Clon-
tech, Palo Alto, Calif) and amplified by PCR using Platinum Taq
(Invitrogen). The following primer pairs were used for the respective
genes: MnSOD: 5’-ATCGAAGCTTTTGAGCCGGGC AGTGTG-
C-3=, 5=-ATCGCGGCCGCTATCTGGGCTGTAACAT-3=, Bfl/A1:
5=-ATCGAAGCTT ACAGACTGTGAATTTGGA-3=, 5=-ATCGC-
GGCCGCTCAACAGTATTGCTTCA-3=, cIAP-2: 5=-TCTACAT-
ATTCAACTTTCCCCGCCGGG-3=, 5=-AACTTTCTCCAGGTCC-
AAAATGAAT AA-3=. As a control, GAPDH cDNA was amplified
using the primers 5=-GTGAGGAGGGGAG ATTCAG-3= and 5=-
GCATCCTGGGCTACACTG-3=. PCR products were resolved on
a 0.8% agarose gel.
Western Immunoblot
Whole cell lysates were prepared from cells treated as described,
using the radioimmunoprecipitation assay lysis buffer. Proteins (50
g/lane) were resolved on a 10% sodium dodecyl sulfate gel and
transferred to nitrocellulose membranes (Bio-Rad, Hercules,
Calif). Membranes were blocked in 5% milk, triethanolamine-
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with primary antibodies against Akt, phospho-Akt, GSK, and
-tubulin.
Apoptosis Assays
NSCLC cells at 60% confluency were treated with the conditions
as described for 24 hours. Caspase-3 activity was determined by
the addition of an APC-DEVD protein conjugate (Calbiochem) to
cellular lysates containing 25 g of protein. Fluorescence of
caspase-3–cleaved protein conjugates was detected on a micro-
plate spectrophotometer SpectraMAX Gemini (Molecular De-
vices, Sunnyvale, Calif). DNA fragmentation was measured using
the Cell Death Detection ELISA Plus kit (Roche, Indianapolis,
Ind) according to the manufacturer’s instructions.
Cell Survival Assays
NSCLC cells were thinly plated and then treated with nothing,
butyrate (500 mol/L), LY (25 mol/L), or both compounds for
48 hours. Drug-containing media were removed, and cells were
then incubated in drug-free media for 5 days. Colonies were then
fixed and stained by sequentially incubating the cells in 1% glu-
taraldehyde and 0.5% crystal violet for 15 minutes each. Colonies
were then counted per 6 mm2 in triplicate and are reported as
percent cell survival.
Xenograft Development and Treatment
Experiments in this study were performed in accordance with a
written protocol approved by our institutional animal care and use
committee. Human NSCLC xenografts were generated in athymic
nude mice (Taconic, Germantown, NY) by injecting 2 106 A549
cells suspended in serum-free Roswell Park Memorial Institute
(100 L/injection site) into each flank of the animal. Once the
tumors achieved a volume of 0.5 cm3 the mice were randomized to
receive no treatment (n  3 mice), butyrate (8 mg/mL in drinking
water) (n  4 mice), LY (100 mg/kg intraperitoneally twice
weekly) (n  4 mice), or both butyrate and LY at the same doses
(n  4 mice). Tumors were measured, and volumes were calcu-
lated (volume  long axis  short axis2) every other day for 18
days. Data are expressed as the mean standard error of mean. At
the conclusion of the treatment period, mice were euthanized and
tumors were harvested.
Xenograft Tissue Analysis
After euthanasia, xenografts were harvested and snap-frozen in
liquid nitrogen. Apoptosis in the xenografts was determined by
terminal deoxynucleotide transferase-mediated dUTP nick-end la-
beling (TUNEL) analysis. Western blot analysis was performed by
homogenizing frozen tissue in radioimmunoprecipitation assay,
resolving 50 g protein by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and immunoblotting for Akt, phospho-Akt,
acetylated histone H3, MnSOD, and RNA pol II.
Statistical Analysis and Data Interpretation
Where appropriate, statistical significance was determined by Stu-
dent t test or analysis of variance tests. The study design, data
analysis, interpretation, and decision to submit this article for
publication were not influenced by any outside funding agency.
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Inhibition of PI3K/Akt Reduces Histone Deacetylase
Inhibitor-Induced Activation of NF-B
To test the hypothesis that LY would abrogate the butyrate-
induced upregulation of NF-B, the transactivation poten-
tial of RelA/p65, the transcriptionally active NF-B subunit,
was determined through transient transfection assays in
several NSCLC cell lines. In each of the 4 cell lines exam-
ined, butyrate dramatically enhanced the transactivation po-
tential of RelA/p65, and this effect was significantly atten-
uated by the addition of LY (Figure 1, A).
To determine whether butyrate and LY had similar in-
fluences on endogenous NF-B–regulated genes, NSCLC
cells were treated as noted and semiquantitative RT-PCR
was performed. In each cell line, butyrate enhanced tran-
scription of MnSOD, Bfl/A1, and cIAP-2 and the addition of
LY suppressed transcription of these same genes to basal
levels (Figure 1, B). Confirmation that LY was affecting its
intended molecular target is demonstrated in Figure 1, C.
Although butyrate did not affect phospho-Akt levels, LY
did completely block Akt activity as measured by dramatic
reductions in phospho-Akt and phospho-GSK levels.
Collectively, these data suggest that the HDI butyrate
up-regulates the transcriptional activity of NF-B by en-
hancing the transactivation potential of RelA/p65 and that
LY blocks this effect. Moreover, this correlates with the
activation or repression of endogenous NF-B–dependent
genes in NSCLC after treatment with butyrate or LY, re-
spectively. Thus, HDI-mediated NF-B activation requires
the presence of activated PI3K/Akt, but HDIs do not acti-
vate PI3K/Akt.
Combined Histone Deacetylase Inhibitor and
LY294002 Enhances Apoptosis in NSCLC
We next sought to determine whether inhibition of histone
deacetylase and PI3K/Akt activity would promote apoptosis
in our NSCLC cell model. As shown in Figure 2, A and B,
there was significantly enhanced caspase-3 activation (P 
.002) and DNA fragmentation (P  .013) after combined
therapy relative to either compound alone. In an effort to
establish that the induction of apoptosis in NSCLC after
treatment with LY and butyrate correlated with cell death
and that these cell death effects persisted, 48-hour cell
survival assays were performed. NSCLC cells treated with
both butyrate and LY had significantly less survival than
cells treated with either butyrate or LY alone (Figure 2, C).
These experiments provide a definitive biologic link (ap-
optosis) to the molecular events previously examined in
Figure 1 and prior studies from our group and others.4,14
Combined Butyrate and LY294002 Provides
Synergistic Killing In Vivo
It is increasingly recognized that alterations in signal trans-
duction pathways and their resulting cellular biologic events
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formed solely in cell culture. To determine whether our in
vitro observations would translate to a more clinically rel-
evant model, we developed an NSCLC (A549) xenograft
model. The A549 cell line was selected on the basis of prior
xenograft studies performed in the laboratory in which the
Figure 1. A, NSCLC cells were treated with nothing, butyrate, LY,
or both drugs. NF-B–dependent transcriptional activity was
determined by (A) Gal4-p65 luciferase reporter genes and (B)
transcription of MnSOD, Bfl/A1, and cIAP-2 by RT-PCR. C, Identi-
cally treated cells were analyzed by Western blotting for the
proteins Akt, phospho-Akt, acetyl-H3, and phospho-GSK. (†P <
.006 vs no treatment, and * P< .02 vs butyrate.) RLU, Relative light
unit.A549 xenografts were noted to have a more predictable
The Journal of Thoracicgrowth pattern relative to other xenografts created using
NSCLC cells.
Combined systemic treatment with butyrate and LY re-
sulted in significantly reduced tumor growth rates relative to
untreated controls or tumors treated with either drug alone
(Figure 3). This combinatorial treatment resulted in syner-
gistic reduction in tumor growth compared with butyrate
alone. Although xenografts treated with LY alone grew
slightly slower over time, only the combined therapy re-
sulted in essentially no tumor growth relative to the tumor
volume at the initiation of treatment (P  .005).
Although the treatment of NSCLC xenografts with both
butyrate and LY completely inhibited tumor growth in vivo,
it was unclear whether this was the result of cell-cycle arrest
or the induction of apoptosis. To experimentally address
Figure 2. NSCLC cells were treated with nothing, butyrate (500
mol/L), LY (25 mol/L), or both drugs, and apoptosis was mea-
sured by (A) caspase-3 activity and (B) DNA fragmentation. C,
NSCLC cells were treated as above, and survival was determined
by clonogenic survival (survival expressed relative to untreated
controls). (†P < .002 and *P < .013 vs all other treatment
conditions.)this, TUNEL analysis was performed on explanted tumor
and Cardiovascular Surgery ● Volume 130, Number 5 1425
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than treatment with either drug alone (Figure 4, A).
To confirm that butyrate and LY were in fact reaching
the tumor and their intended molecular targets, Western blot
analyses were performed on the tumor xenografts (Figure 4,
B). As seen previously in experiments performed in vitro,
the addition of LY depressed phospho-Akt levels without
significantly affecting the overall levels of Akt. In each
treatment condition, the addition of butyrate did not appear
to have any significant effect on Akt or phospho-Akt levels.
Xenografts from animals treated with butyrate demonstrated
enhanced acetylation of histone H3, suggesting global tu-
mor hyperacetylation. These target validation studies indi-
cate that both butyrate and LY were active in the NSCLC
xenografts. Collectively, these in vivo experiments provide
“proof of principle” of our in vitro cell culture experiments.
Discussion
The majority of patients with NSCLC present with ad-
vanced stage disease and are commonly managed with
systemic chemotherapy, either with or without the local
treatment modalities of surgery or radiation.15 Currently
available chemotherapeutic agents that nonspecifically tar-
get the DNA of rapidly dividing cells afford marginal pa-
tient survival benefit when used as isolated therapy.16,17
These sobering results have prompted an intense search for
novel therapies that target intracellular or extracellular pro-
teins that are relevant to each individual tumor and its
biology.
Recently, interest in the more novel class of chemothera-
Figure 3. NSCLC xenografts were treated with nothing, butyrate
(8 mg/mL in drinking water), LY (100 mg/kg intraperitoneally twice
weekly), or both drugs, and tumors were measured every other
day. Volumes were calculated and expressed as relative tumor
growth (V/Vo)  standard error of mean (P < .005).peutic agents, the HDIs, has been generated on the basis of
1426 The Journal of Thoracic and Cardiovascular Surgery ● Novpreclinical studies showing that these agents are capable of
inducing cellular differentiation, apoptosis, and cell cycle
arrest.18 A phase I clinical trial of the HDI depsipeptide, in
patients with advanced-stage solid tumor malignancies in-
cluding NSCLC, found that only 1 of 37 patients treated
showed a clinical response. This single patient demon-
strated greater than 50% reduction in the mediastinal, ret-
roperitoneal, and supraclavicular adenopathy associated
with metastatic renal cell carcinoma.19 Similarly, Kelly and
Figure 4. A, Xenografts were harvested and apoptosis was de-
termined by TUNEL analysis. B, Western blots were performed on
xenografts for phospho-Akt, Akt, acetyl-histone H3, MnSOD, and
RNA pol II.colleagues20 found that suberoylanilide hydroxamic acid,
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efficacy.
Chromatin hyperacetylation is thought to correlate with
increased transcriptional activity. However, HDIs affect
transcriptional activity of only 10% of the entire genome,
and an equal number of genes are inhibited as are activ-
ated.21 Although mechanisms underlying biologic responses
of malignant cells to HDI therapy remain poorly elucidated,
previously described mechanisms of action include induction
of cell-cycle arrest through p21 up-regulation and enhanced
transcription of the tumor suppressor gene gelsolin.18
Genomic aberrations, typical of malignant transforma-
tion, have been studied in NSCLC.22 The most frequently
amplified segment of DNA is located at chromosome
3q26.3 in squamous cell carcinoma of the lung, and subse-
quent fluorescent in situ hybridization analysis found the
second most frequently amplified gene was PI3K (second
only to somatostatin).22 Further analyses have shown that
PI3K/Akt is significantly overexpressed in 90% of NSCLC
cell lines,23 and that 77% of all lung cancers overexpress the
catalytic subunit of PI3K.24 The role of PI3K/Akt in lung
carcinogenesis is further supported by the fact that both nico-
tine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, an-
other carcinogen found in tobacco smoke, enhance Akt
activity.25 In addition, increased Akt activity has been sug-
gested to have clinical prognostic significance independent
of tumor stage.26,27 Collectively, these studies suggest that
the PI3K/Akt pathway plays a role in the oncogenesis and
progression of NSCLC.
The transcription factor NF-B is also activated by to-
bacco smoke through mechanisms similar to tumor necrosis
factor-dependent activation, and the tobacco-related carcin-
ogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone has
been shown to induce neoplastic transformation of xe-
nografted human bronchial endothelial cells.28,29 NF-B is a
downstream target that is activated by Akt, which stimulates
nuclear translocation of the transcriptionally active p50/p65
heterodimers and also is required for full up-regulation of the
transactivation potential of RelA/p65.4,6 NF-B is also ac-
tivated by chemotherapy, and its activation contributes sig-
nificantly to the resistance of NSCLC to apoptosis induced
by traditional chemotherapeutic agents as well as HDI ther-
apy. 1,2,12,14,30
In this study we addressed the hypothesis that pharma-
cologic inhibition of the PI3K/Akt pathway would inhibit
NF-B and sensitize NSCLC cells to apoptosis after histone
deacetylase inhibition. As shown in Figure 1, butyrate dra-
matically activated NF-B–dependent transcription in vitro,
and this effect was blocked by LY. Subsequent studies
correlated PI3K/Akt inhibition with the sensitization of
NSCLC cells to butyrate-induced apoptosis both in vitro
and in vivo (Figures 2 and 3). This combination therapy was
also found to have synergistic tumoricidal effects in our in
The Journal of Thoracicvivo model. Our results are similar to those reported by
other groups, although in different solid tumors. Wang and
colleagues31 found that combined butyrate and wortmannin
(another PI3K/Akt inhibitor) resulted in significant in vitro
and in vivo apoptotic cell death in a colon cancer model.
Rahmani and colleagues32 found that combined LY and
butyrate also induced significant apoptosis on human leu-
kemic cells, but that the effect of the PI3K inhibitor LY
appeared to be mediated through a MAP kinase-dependent
pathway and not directly through Akt.
A necessary component of drug discovery and the asso-
ciated preclinical studies is the determination of target val-
idation in the tissue or tumor of interest. As shown in this
study both butyrate and LY appeared to reach the tumor and
resulted in the perturbation of their intended molecular
targets. It is certainly possible, and indeed likely, that other
proteins that we did not screen for were also affected by
these compounds and that these effects may have contrib-
uted to the observed apoptosis. For a more complete picture
of all affected molecules by this combined therapy, future
studies would need to have either gene-array or proteomic
analyses performed on the explanted tumor.
This study builds on previous studies that have shown
that direct molecular inhibition of NF-B sensitizes NSCLC
to chemotherapy and HDI-induced apoptosis.1,2,4 More re-
cently, we showed that pharmacologic inhibition of NF-B
with the proteasome inhibitor Velcade (Millennium Phar-
maceuticals, Cambridge, Mass) also sensitizes NSCLC to
HDI-induced apoptosis.30 In an effort to potentially expand
potential drug targets we sought to look upstream at signal
transduction pathways, like PI3K/Akt, that activate NF-B.
The 2 well-known PI3K/Akt inhibitors, LY and Wortman-
nin, are both insoluble in water and thus are unlikely to be
used clinically. More recently, however, naltrindole, a
-opioid receptor antagonist similar to naloxone, has been
shown to inhibit Akt phosphorylation at doses within the
same order of magnitude of what has been achieved in
animals.33 Castillo and colleagues34 also identified several
phosphatidylinositol ether lipid analogues that inhibited Akt
activity at low concentrations and enhanced apoptosis by
20- to 30-fold in cancer cell lines that express high levels of
Akt.
Conclusion
This study indicates that combined inhibition of histone
deacetylase activity and PI3K/Akt induces apoptosis in
NSCLC both in vitro and in vivo. We also provided impor-
tant preliminary target validation evidence for each com-
pound of this combined treatment approach. This combined
treatment approach may benefit patients with NSCLC as
more soluble inhibitors of the PI3K/Akt pathway are devel-
oped and become commercially available.
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Discussion
Dr Tom Waddell (Toronto, Ontario, Canada). Why do you think
it was only tumoristatic given all the apoptosis you found in the
explanted tumors?
Dr Rundall. On the TUNEL assay there were nests of apopto-
tic cells interspersed between cells that were at that time nonapop-
totic, and so I think the net effect was a tumoristatic growth
pattern, although, as you noted, there was significant apoptosis.
Dr David S. Schrump (Bethesda, Md). I congratulate you on
a very clinically relevant study. I think it actually highlights the
overlapping strategies that are now being used to combine histone
deacetylase inhibitors with other small molecular compounds that
are targeting NF-B and survival pathways. Similar efforts have
been under way with suberoylanilide hydroxamic acid and dep-
sipeptide and combinations of other drugs, including LY or flavo-
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up-regulated paradoxically by histone deacetylase exposure.
I have just a couple of questions. The LY compound that you
used, you imply that it is specific for the PI3/Akt pathway, but it
really is also a PKC inhibitor. Do you have any data regarding the
effects of this compound on PKC signaling in your model?
Dr Rundall. We looked at several pathways, but we did not
look at PKC. We looked at the JNK, p38, MAPK, and DNA-PK
pathways and inhibitors to those specific pathways and found that
LY significantly reduced the butyrate-induced activation of PI3K/
Akt significantly more than any of the other pathways.
Dr Schrump. And both of those pathways will actually funnel
through NF-B, which is an upstream mediator of p21 and so
forth. In your apoptotic experiment, which is very impressive in
the in vivo model, did you look at p21 expression or anything else
that is a known tumor suppressor up-regulated by histone deacety-
lase inhibitors that abrogates the cytotoxicity of these compounds?
It is a nice translational end point to be looking at as well.
Dr Rundall. We did not look specifically at p21, but that is a
good end point to evaluate.
Dr Schrump. And the last question, what happens if you
withdraw therapy from those animals that had the combinationThe Journal of ThoracicDr Rundall. We did not withdraw the drug. At that time we
harvested the xenografts and analyzed them, but that would remain
to be studied as well.
Dr Schrump. Thank you very much.
Dr Thomas A. D’Amico (Durham, NC). That was a nice
presentation, and this continues on Dr Jones’ long work on HD
inhibition.
Would you comment on the clinical applicability of this
strategy. How do we need to go from where we are now to the
use of these agents in a phase I trial? Do you think that is a
feasible goal?
Dr Rundall. There are several HDIs currently in phase I and II
trials, and these are generally well tolerated. As far as the Akt/
PI3-kinase inhibitors, there is a significant amount of work being
performed to develop more pharmacologically available com-
pounds, as well as more specific inhibitors of Akt. There is a recent
study by Phil Dennis at the National Cancer Institute where he
reports 5 new water-soluble compounds that inhibit Akt suggesting
that they could be used clinically.
Dr D’Amico. What are the toxicity issues with Akt inhibitors?
Dr Rundall. Specifically with LY there is skin necrosis at the
site of injection, as well as decreased appetite and some malaise inG
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